Lexaria Bioscience Corp. - Common Stock (LEXX)

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Lexaria Bioscience shares are trading lower by 6.5% Thursday morning. The company finalized agreements for a registered direct offering.

The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session.

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

LEXX stock results show that Lexaria Bioscience missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024.

Some penny stocks can be diamonds in the rough. These A-rated penny stocks are all solid picks for a portfolio this month.

A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.

It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning!

For a growth investor, one of the top advantages of A-rated penny stocks is that they have the potential for oversized profits.

LEXX stock results show that Lexaria Bioscience beat analyst estimates for earnings per share the second quarter of 2024.

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.

Lexaria Bioscience just reported results for the first quarter of 2024.